The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation
Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer
Vital AstraZeneca therapy may transform lives of people with certain breast and prostate cancers
Data demonstrates a sound safety and tolerability profile for therapy during phase 1 clinical trial
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Individual receives AVA6000 treatment as part of additional dose escalating study
Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP
Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group
Study demonstrated a reduction in viral replication in the upper respiratory tract as well as influenza infection
Five vital new appointments made to regulator’s insight, perspective and advice group
Results from trial showed a long-term response among specific lung cancer population
Collaboration comes after renewed focus on key therapeutic areas of immunology and oncology
Therapy candidates chosen for lead projects targeting mast cell driven diseases
Therapy is a positive modulator and has demonstrated that it can improve learning and memory